|
| related topics |
| {product, liability, claim} |
| {product, candidate, development} |
| {product, market, service} |
| {stock, price, operating} |
| {property, intellectual, protect} |
| {cost, operation, labor} |
| {provision, law, control} |
| {control, financial, internal} |
| {loan, real, estate} |
|
|
Future sales of Colazal, Xifaxan and our other marketed products might be less than expected.
Our ability to increase revenue in the future will depend in part on our success in in-licensing or acquiring additional pharmaceutical products.
Regulatory approval of our product candidates is time-consuming, expensive and uncertain, and could result in unexpectedly high expenses and delay our ability to sell our products.
Our intellectual property rights might not afford us with meaningful protection.
We could be exposed to significant product liability claims that could prevent or interfere with our product commercialization efforts.
Intense competition might render our products noncompetitive or obsolete.
If third-party payors do not provide coverage or reimburse patients for our products, our ability to derive revenues will suffer.
We are dependent on third parties to manufacture our products.
Failure to manage growth could increase expenses faster than revenue.
If we do not maintain our recently attained profitability or if we incur losses in the future, then the value of our common stock is likely to fall.
We continue to face challenges in integrating InKine operations and personnel.
If ALW Partnership terminates our license agreement with them, then ALW Partnership could prevent the development, manufacture or sale of Visicol and INKP-102.
Our results of operations might fluctuate from period to period, and a failure to meet the expectations of investors or the financial community at large could result in a decline in our stock price.
Our stock price is volatile.
Antitakeover provisions could discourage a takeover that stockholders consider to be in their best interests or prevent the removal of our current directors and management.
Full 10-K form ▸
|
|
| related documents |
| 1009356--3/15/2007--SALIX_PHARMACEUTICALS_LTD |
| 911649--4/2/2007--STRATEGIC_DIAGNOSTICS_INC/DE/ |
| 816284--2/20/2008--CELGENE_CORP_/DE/ |
| 880432--9/26/2008--MISONIX_INC |
| 810084--4/2/2007--BIOJECT_MEDICAL_TECHNOLOGIES_INC |
| 834306--3/16/2006--BIOSITE_INC |
| 1000694--3/6/2006--NOVAVAX_INC |
| 926763--3/16/2007--ASV_INC_/MN/ |
| 862668--10/12/2010--ESCALON_MEDICAL_CORP |
| 1006195--3/15/2007--MATRIXX_INITIATIVES_INC |
| 886163--3/16/2007--LIGAND_PHARMACEUTICALS_INC |
| 38074--5/30/2008--FOREST_LABORATORIES_INC |
| 911649--3/31/2006--STRATEGIC_DIAGNOSTICS_INC/DE/ |
| 882873--9/21/2009--UROLOGIX_INC |
| 1006045--3/30/2007--IRIDEX_CORP |
| 724004--6/29/2009--MESA_LABORATORIES_INC_/CO |
| 28626--9/13/2007--LIFECORE_BIOMEDICAL_INC |
| 736822--8/1/2006--IMMUCOR_INC |
| 724004--6/29/2010--MESA_LABORATORIES_INC_/CO |
| 873364--3/13/2006--CEPHALON_INC |
| 893160--2/16/2007--VENTANA_MEDICAL_SYSTEMS_INC |
| 880432--9/28/2009--MISONIX_INC |
| 780127--1/12/2006--SYNOVIS_LIFE_TECHNOLOGIES__INC |
| 926763--3/16/2006--ASV_INC_/MN/ |
| 739944--3/11/2008--MEDTOX_SCIENTIFIC_INC |
| 736822--7/24/2008--IMMUCOR_INC |
| 109831--3/22/2006--INAMED_CORP |
| 862668--9/29/2008--ESCALON_MEDICAL_CORP |
| 1043894--4/15/2009--ENVIRO_VORAXIAL_TECHNOLOGY_INC |
| 894237--6/29/2006--VISION_SCIENCES_INC_/DE/ |
|